The Autosomal Dominant Hypocalcemia Type 1 Market Size is predicted to grow at a 2.96% CAGR during the forecast period for 2024-2031.
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare inherited condition characterized by abnormally low blood calcium levels. This condition is caused by mutations in the CASR gene, which produces the calcium-sensing receptor protein. The calcium-sensing receptor is involved in blood calcium homeostasis regulation. The receptor triggers the production of parathyroid hormone, which helps elevate low calcium levels. The rising frequency of the condition, increased public awareness, advancing technology, and the discovery of new drugs are the main factors propeling the global market for autosomal dominant hypocalcemia type 1.
Additionally, a collaboration between academics, patient advocacy groups, healthcare professionals, and regulators boosts market revenue growth. Nonetheless, it is anticipated that the global autosomal dominant hypocalcemia type 1 market's revenue growth will be constrained by unfinished research and ignorance of ADH.
The autosomal dominant hypocalcemia Type 1 market is segmented based on treatment and end-user. Based on treatment, the market is segmented into Calcium Analogs and Vitamin Analogs. The end-user segment is categorised into Hospitals, Clinics, and Others.
The calcium analogs category is expected to hold a major global market share in 2023. The cornerstone of treating autosomal dominant hypocalcemia type 1 is calcium analogs, such as calcitriol and calcium supplementation. They are generally accessible and available, and they are useful in controlling the symptoms of the disease. Since ADH1 therapeutic choices are currently restricted, calcium analogs are frequently the sole long-term alternative available to patients with the disorder. Healthcare professionals find calcium analogs to be an appealing alternative due to their low cost and high effectiveness. The use of calcium analogs in the therapy of ADH1 is supported by a sizable body of clinical evidence.
Hospitals hold the biggest revenue share in the global autosomal dominant hypocalcemia type 1 market due to their vast patient pool, making them the major healthcare facility. Furthermore, the need for quick diagnoses and therapies grows along with the number of cases of hypocalcemia. Additionally, hospitals offer cutting-edge diagnostic and management technologies to highly qualified healthcare professionals. High patient satisfaction rates and reimbursement policies also contribute to this segment's revenue growth, which in turn drives the expansion of the market as a whole.
The North American autosomal dominant hypocalcemia Type 1 market is expected to report the significant market share in revenue in the near future. North America has a well-respected healthcare system with state-of-the-art hospitals, highly qualified medical staff, and state-of-the-art medical technology. Moreover, North America is home to a sizable portion of the world's best scientific institutes. Because of the ageing population & increased risk of hypocalcemia in the elderly, there is a growing demand in the region for autosomal dominant hypocalcemia type 1 diagnostic and management drugs.
In addition, Europe is likely to grow rapidly in the global autosomal dominant hypocalcemia Type 1 market due to the rarity of the illness. In Europe, ADH1 is often treated by a multidisciplinary team of healthcare professionals that includes endocrinologists, geneticists, and other specialists. Due to the rarity of ADH1, there may be little business interest in creating specialist treatments for this ailment.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 2.96% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Treatment, And End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
F. Hoffmann-La Roche Ltd., Abbott Laboratories Inc., BridgeBio Inc., and Shire (Takeda). |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Autosomal Dominant Hypocalcemia Type 1 Market Snapshot
Chapter 4. Global Autosomal Dominant Hypocalcemia Type 1 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Autosomal Dominant Hypocalcemia Type 1 Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Autosomal Dominant Hypocalcemia Type 1 Industry Trends
Chapter 5. Autosomal Dominant Hypocalcemia Type 1 Market Segmentation 1: By Treatment, Estimates & Trend Analysis
5.1. Market Share by Treatment, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatment:
5.2.1. Calcium Analogs
5.2.2. Vitamin Analogs
Chapter 6. Autosomal Dominant Hypocalcemia Type 1 Market Segmentation 2: By End user, Estimates & Trend Analysis
6.1. Market Share by End user, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End users:
6.2.1. Hospitals
6.2.2. Clinics
Chapter 7. Autosomal Dominant Hypocalcemia Type 1 Market Segmentation 6: Regional Estimates & Trend Analysis
7.1. Global Autosomal Dominant Hypocalcemia Type 1 Market, Regional Snapshot 2023 & 2031
7.2. North America
7.2.1. North America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
7.2.3. North America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
7.3. Europe
7.3.1. Europe Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
7.3.3. Europe Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
7.4. Asia Pacific
7.4.1. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Hong Kong
7.4.1.7. Southeast Asia
7.4.1.8. Rest of Asia Pacific
7.4.2. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
7.4.3. Asia Pacific Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts By End user, 2024-2031
7.5. Latin America
7.5.1. Latin America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
7.5.3. Latin America Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
7.6. Middle East & Africa
7.6.1. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.6.1.1. GCC Countries
7.6.1.2. Israel
7.6.1.3. South Africa
7.6.1.4. Rest of Middle East and Africa
7.6.2. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
7.6.3. Middle East & Africa Autosomal Dominant Hypocalcemia Type 1 Market Revenue (US$ Million) Estimates and Forecasts by End user, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. BridgeBio Inc.
8.2.1.1. Business Overview
8.2.1.2. Key Product/Service Offerings
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. Shire (Takeda)
8.2.3. Abbott Laboratories Inc.
8.2.4. F. Hoffmann-La Roche AG
Autosomal Dominant Hypocalcemia Type 1 Market By Treatment-
Autosomal Dominant Hypocalcemia Type 1 Market By End-User-
Autosomal Dominant Hypocalcemia Type 1 Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
